Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.
Helexva has raised $2.3M in total funding. The most recent round was Seed. The last funding was announced in March 2024.
Helexva's investors include UPMC Enterprises.
Helexva is headquartered in Pittsburgh, United States.
Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.
Helexva is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Helexva — Funding & Investors." VCBacked, March 2, 2024, https://www.vcbacked.co/company/helexva. Accessed September 7, 2026.
VCBacked. (2024). Helexva — Funding & Investors. Retrieved September 7, 2026, from https://www.vcbacked.co/company/helexva
{{cite web |title=Helexva — Funding & Investors |url=https://www.vcbacked.co/company/helexva |website=VCBacked |access-date=September 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated